New
Global ETF Survey 2026: Answer now →
Help us improve your experience. Please confirm your investor type:
Global ETF Survey 2026
The ETF Industry Is Evolving Fast
From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.
203780 ETF · Mirae Asset TIGER NASDAQ BIO ETF
The 203780 Exchange Traded Fund (ETF) is provided by Mirae Asset Global Investments. It is built to track an index: NASDAQ Biotechnology Index. The 203780 ETF provides physical exposure, so by buying it you actually own parts of all the 194 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update Today at 12:00 AM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.+4.10%
Last price
â‚©32,905
1M perf.
+4.69%
1M flows
-€3.9M
AuM
€49M
TER
0.3%
Rating
Not rated
ESG Consensus®
203780
â‚©32,905
Performance & flows
Segment for quartile rank
March 3, 2026 → June 3, 2026
Create a free account to view the flows graph
203780
â‚©32,250
+0.73%
US Health Care
-4.90%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +4.69%  | +0.73%  | +53.82% | +61.99% | +67.20% | -1.45% | +3.85% | +6.30% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
ISIN
KR7203780002
AuM
€49M
TER
0.3%
Replication rating
Not rated
ESG Consensus®
More details
NAV
6/3/2026
â‚©32,250
1D NAV change
N/A
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
194
Inception date
8/27/2014
Jurisdiction
South Korea
Distribution
Macedonia, The Former Yugoslav Republic of
Moldova, Republic of
Tanzania, United Republic of
Congo, The Democratic Republic of the
Democratic People's Republic of Korea
Legal structure
Open-end Investment Trust
Base currency
KRW
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The TIGER NASDAQ BIO ETF seeks investment results that corresponds generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index (KRW).
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialSimilar ETFs in your region
00678
1M perf.
-3.84%
TER
1.01%
HTEC
1M perf.
+3.59%
TER
0.8%
IBB
1M perf.
+0.69%
TER
0.44%
BTEC
1M perf.
+0.58%
TER
0.35%
IBBQ
1M perf.
+0.78%
TER
0.19%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +0.73% | +53.82% | +61.99% | +67.20% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
USA
81.48%
Bermuda
1.72%
United Kingdom
1.69%
Ireland
1.55%
Unavailable
11.81%
Other
1.75%
Sectors
Health Care
81.26%
Unavailable
18.73%
Diversification
Total weight of top 15 holdings out of 194
Top 15 holdings
Data as of April 30, 2026
AMGEN-T
GILEAD SCIENCES
VERTEX PHARMACEUTICALS
REGENERON PHARMACEUTICALS
ALNYLAM PHARMACEUTICALS
INSMED
BIOGEN INC
REVOLUTION MEDICINES INC
Create a free account to view top holdings
UTD THERAPEUT
US04016X1019
ROYALTY PHARMA
MODERNA INC
ILLUMINA
ROIVANT SCIENCES LTD
INCYTE
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Issuer
Mirae Asset Global Investments
Mirae Asset Global Investments ID Card
Number of funds
100
Total AuM
€38.26B
Expense ratio range
0.05% - 1%
Average expense ratio
0.3878%
Top 5 funds by Mirae Asset Global Investments
| AuM | ||
|---|---|---|
396500 | Mirae Asset TIGER Fn Semiconductor TOP10 ETF | €7.88B |
102110 | Mirae Asset TIGER 200 ETF | €6.79B |
133690 | Mirae Asset TIGER NASDAQ 100 ETF | €6.38B |
381170 | Mirae Asset TIGER US Tech TOP10 INDXX ETF | €2.46B |
292150 | MIRAE ASSET TIGER TOP 10 ETF | €1.54B |
Frequently asked questions about 203780
What does Mirae Asset TIGER NASDAQ BIO ETF, 203780, invest in?
203780 is a Passive ETF. This ETF provides exposure to US Equities.
Which benchmark or index does 203780 replicate?
203780 tracks the NASDAQ Biotechnology Total Return Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of 203780?
203780 carries a total expense ratio (TER) of 0.3%, indicating the annual cost for holding the fund.
When was 203780 launched?
203780 was introduced to the market on August 27, 2014. It trades on Macedonia, The Former Yugoslav Republic of, among other exchanges
Who is the ETF issuer of 203780?
Mirae Asset TIGER NASDAQ BIO ETF, 203780, is provided by Mirae Asset Global Investments. Learn more about Mirae Asset Global Investments here.
What is the current assets under management (AUM) of 203780?
203780 oversees €49M in assets as of June 3, 2026.
How has 203780 performed lately?
Based on data from June 3, 2026, 203780 returned 4.69% over the past month, 0.73% over the last three months and 6.30% year-to-date.
What are the latest inflows or outflows for 203780?
As of June 3, 2026, 203780 recorded net flows of -€3.8M over the last month and -€13M year-to-date.
Does 203780 distribute dividends?
203780 follows a distributing dividend policy, meaning it pays out income to investors. As of June 3, 2026, its 12-month trailing yield was 0.50%.
What are the main country or region exposures of 203780?
As of April 30, 2026, 203780 has significant geographic allocations in USA, Bermuda and United Kingdom.
In which sector or theme does 203780 invest in?
As of April 30, 2026, 203780 focuses largely on Health Care.
How many securities does 203780 hold and how diversified is it?
As of April 30, 2026, 203780 holds 194 positions in its portfolio, with 49.30% of assets concentrated in its top 15 holdings.
What are the main positions in 203780?
As of April 30, 2026, 203780 top three holdings include AMGEN-T, GILEAD SCIENCES and VERTEX PHARMACEUTICALS.
What is the base currency of 203780?
The base currency of 203780 is KRW.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
